1.Bilateral facial nerve palsy in Kawasaki disease.
Terence C W LIM ; Wee Song YEO ; Kah Yin LOKE ; Swee Chye QUEK
Annals of the Academy of Medicine, Singapore 2009;38(8):737-738
Anti-Inflammatory Agents
;
therapeutic use
;
Aspirin
;
therapeutic use
;
Child
;
Facial Nerve Diseases
;
diagnosis
;
etiology
;
Facial Paralysis
;
diagnosis
;
etiology
;
Humans
;
Immunoglobulins, Intravenous
;
Male
;
Mucocutaneous Lymph Node Syndrome
;
complications
;
diagnostic imaging
;
Platelet Aggregation Inhibitors
;
therapeutic use
;
Prednisolone
;
therapeutic use
;
Ultrasonography
;
Warfarin
;
therapeutic use
3.Yemen’s Cholera Epidemic Is a One Health Issue
Qin Xiang NG ; Michelle Lee Zhi Qing DE DEYN ; Wayren LOKE ; Wee Song YEO
Journal of Preventive Medicine and Public Health 2020;53(4):289-292
Yemen has been faced with the worst cholera epidemic of modern times, with more than 1 million suspected cases and 3000 deaths at the time of writing. This problem is largely due to the longstanding civil war between pro-government forces and the Houthi armed movement, which has severely damaged already vulnerable sanitation and healthcare facilities and systems in the country. It is further compounded by a dire lack of basic amenities, chronic malnutrition, and unfavourable weather conditions. Another contributory component may be aerial transfer by cholera-infected chironomid insects. To contain the spread of cholera in Yemen, a nation-wide armistice should be negotiated, and national and local committees must be convened to coordinate efforts on the ground. Community isolation facilities with proper sanitation, reliable disposal systems, and a clean water supply should be set up to isolate and treat sick patients. The continuity of vaccination programmes should be ensured. Public health campaigns to educate local communities about good hygiene practices and nutrition are also necessary. The One Health paradigm emphasizes a multi-sectoral and transdisciplinary understanding and approach to prevent and mitigate the threat of communicable diseases. This paradigm is highly applicable to the ongoing cholera crisis in Yemen, as it demands a holistic and whole-of-society approach at the local, regional, and national levels. The key stakeholders and warring parties in Yemen must work towards a lasting ceasefire during these trying times, especially given the extra burden from the mounting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak worldwide.
4.Nineteen-year experience of paediatric renal transplantation in Singapore.
Kar Hui NG ; Pramod SHRESTHA ; Eric ARAGON ; Yew Weng LAU ; Wee Song YEO ; Yiong Huak CHAN ; Prabhakaran KRISHNAN ; Hui Kim YAP
Annals of the Academy of Medicine, Singapore 2009;38(4):300-309
INTRODUCTIONRenal transplantation is the treatment of choice for children with end-stage renal failure (ESRF). The paediatric renal transplant programme in Singapore was initiated in 1989. This study aimed to examine our outcomes over the 19-year period from 1989 to 2007.
MATERIALS AND METHODSA total of 38 renal transplants were performed at our centre. Another 4 patients with overseas transplants who returned within 3 weeks post-transplant were included. The proportion of living donor (LD) transplants was 61.9%. Structural abnormalities and glomerulopathies were the most common aetiologies comprising 33% each. Median age at transplant was 13.9 years and median waiting time was 2.2 years. LD transplant recipients were younger and had a shorter waiting time than deceased donor (DD) recipients.
RESULTSOverall patient survival rates were 95%, 92%, 86% and 86% at 1, 5, 10 and 15 years, respectively. There were 4 deaths, of which 3 were due to infections. Graft survival rates at 1, 5, 10 and 15 years for LD and DD transplants were 100%, 89.5%, 67.3%, 67.3% and 80.8%, 56.5%, 42.2%, 28.3% respectively, and were significantly higher in LD transplants. The main cause of graft loss was rejection following non-adherence. Multivariate analysis showed male gender, late acute rejections and acute tubular necrosis as predictors of graft failure. There was a high incidence of early bacterial infections (42.9%) and cytomegalovirus disease (16.7%).
CONCLUSIONOur graft survival rates for LD transplants were comparable to North American rates, although our DD transplant rates were slightly worse, probably a reflection of the prevailing transplant policies.
Adolescent ; Child ; Child, Preschool ; Female ; Graft Survival ; Humans ; Kidney Failure, Chronic ; surgery ; Kidney Transplantation ; utilization ; Living Donors ; supply & distribution ; Male ; Multivariate Analysis ; Outcome Assessment (Health Care) ; trends ; Postoperative Complications ; epidemiology ; Singapore ; epidemiology ; Survival Analysis ; Young Adult
5.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Sollip KIM ; Yeo Min YUN ; Hyo Jin CHAE ; Hyun Jung CHO ; Misuk JI ; In Suk KIM ; Kyung A WEE ; Woochang LEE ; Sang Hoon SONG ; Hye In WOO ; Soo Youn LEE ; Sail CHUN
Annals of Laboratory Medicine 2017;37(2):180-193
Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.
Anticoagulants/therapeutic use
;
Antidepressive Agents/therapeutic use
;
Antimetabolites, Antineoplastic/therapeutic use
;
Antitubercular Agents/therapeutic use
;
Arylamine N-Acetyltransferase/genetics
;
Coronary Artery Disease/drug therapy/genetics
;
Cytochrome P-450 CYP2C19/genetics
;
Cytochrome P-450 CYP2C9/genetics
;
Cytochrome P-450 CYP2D6/genetics
;
Depressive Disorder/drug therapy/genetics
;
Genotype
;
Isoniazid/therapeutic use
;
Laboratories, Hospital/standards
;
Methyltransferases/genetics
;
Pharmacogenomic Testing/*methods/standards
;
Platelet Aggregation Inhibitors/therapeutic use
;
Pulmonary Embolism/drug therapy/genetics
;
Ticlopidine/analogs & derivatives/therapeutic use
;
Tuberculosis/drug therapy/genetics
;
Vitamin K Epoxide Reductases/genetics
;
Warfarin/therapeutic use